The diabetes management devices market will witness a positive impact during the forecast period owing to the widespread growth of the COVID-19 pandemic. As per Technavio’s pandemic-focused market research, market growth is likely to increase in 2021 as compared to 2020.
With the continuing spread of the coronavirus pandemic, organizations across the globe are gradually flattening their recessionary curve by leveraging technology. Many businesses will go through response, recovery, and renewal phases. Building business resilience and enabling agility will aid organizations to move forward in their journey out of the COVID-19 crisis towards the Next Normal.
Key Considerations for Market Forecast:
- Impact of lockdowns, supply chain disruptions, demand destruction, and change in customer behavior
- Optimistic, probable, and pessimistic scenarios for all markets as the impact of pandemic unfolds
- Pre- as well as post-COVID-19 market estimates
- Quarterly impact analysis and updates on market estimates
The diabetes management devices market is driven by the rising global burden of diabetes. In addition, the growing demand for advanced insulin delivery devices and favorable government initiatives are expected to trigger the diabetes management devices market toward witnessing a CAGR of over 8% during the forecast period.
Gain more insights into the global trends impacting the future of the diabetes management devices market.
Request Free Sample @ https://www.technavio.com/talk-to-us?report=IRTNTR70599
Major Five Diabetes Management Devices Market Participants:
Abbott Laboratories: The company offers a wide range of diabetes management devices such as FREESTYLE LIBRE 3, FREESTYLE LIBRE 2, FREESTYLE OPTIUM / PRECISION NEO, and others.
B. Braun Melsungen AG: The company offers a wide range of diabetes management devices such as Omnitest 5, Omnican fine, Solofix safety and others.
Bionime Corp.: The company offers diabetes monitoring devices such as Max / Max Plus, GE Glucose Meter GM550, and others.
Novo Nordisk AS: The company offers a wide range of diabetes management devices such as NovoPen 4, NovoPen 5, NovoPen Echo, FlexPen, and others.
Eli Lilly and Co.: The company offers Insulin Lispro Injection, Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen, Insulin Lispro Injection Junior KwikPen, and others.
Devices Market 2021-2025: Segmentation
Diabetes management devices market is segmented as below:
- Blood Glucose Monitoring Devices
- Insulin Delivery Systems
- North America
Related Reports on Healthcare Include:
Global Non-insulin Diabetes Therapeutics Market – Global non-insulin diabetes therapeutics market is segmented by type (DPP4 inhibitor, GLP-1 receptor agonist, SGLT2 inhibitor, and others) and geography (North America, Europe, Asia, and ROW).
Request a Free Sample Report
Global Blood Glucose Test Strips Market – Global blood glucose test strips market is segmented by end-user (hospitals and diagnostic laboratories, home care settings, and POL) and geography (North America, Europe, Asia, and ROW).
Request a Free Sample Report
Gain instant access to 17,000+ market research reports by using
Technavio’s SUBSCRIPTION platform
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]